- Conference call to take place at
8:30am ET -
WILMINGTON, Del., March 12,
2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc.
(Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a
clinical-stage biopharmaceutical company, today announced that it
will release its fourth quarter and full year 2024 financial
results before the market opens on Monday, March 17, 2025 via
press release, which will be available on the Company's website
at https://ir.nrxpharma.com/. The Company will host a
conference call to discuss the financial results as well as provide
a corporate update at 8:30am ET the same day.
A live webcast of the conference call will be available on the
Company's website at https://ir.nrxpharma.com/events.
Participants that are unable to join the webcast can access the
conference call via telephone by dialing domestically
+1-800-717-1738 or internationally +1-646-307-1865.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical
company developing therapeutics based on its NMDA platform for the
treatment of central nervous system disorders, specifically
suicidal bipolar depression, chronic pain, and PTSD. The Company is
developing NRX-101, an FDA-designated investigational Breakthrough
Therapy for suicidal treatment-resistant bipolar depression and
chronic pain. NRx plans to file an NDA for Accelerated Approval for
NRX-101 in patients with bipolar depression and suicidality or
akathisia. NRX-101 additionally has potential to act as a
non-opioid treatment for chronic pain, as well as a treatment for
complicated UTI.
NRx has recently initiated a New Drug Application filing for
NRX-100 (IV ketamine) for the treatment of suicidal depression,
based on results of well-controlled clinical trials conducted under
the auspices of the US National Institutes of Health and newly
obtained data from French health authorities, licensed under a data
sharing agreement. NRx was awarded Fast Track Designation for
development of ketamine (NRX-100) by the US FDA as part of a
protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a
development stage healthcare delivery company that intends to
develop a best-in-class network of interventional psychiatry
clinics to offer ketamine transcranial magnetics stimulation (TMS)
and other lifesaving therapies to patients with suicidal depression
and related disorders, together with a digital therapeutic-enabled
platform designed to augment and preserve the clinical benefit of
NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and Section 27A of the Securities
Act of 1933, as amended. Forward-looking statements generally
include statements that are predictive in nature and depend upon or
refer to future events or conditions, and include words such as
"may," "will," "should," "would," "expect," "plan," "believe,"
"intend," "look forward," and other similar expressions among
others. These statements relate to future events or to the
Company's future financial performance, and involve known and
unknown risks, uncertainties and other factors that may cause the
Company's actual results to be materially different from any future
results, levels of activity, performance or achievements expressed
or implied by these forward-looking statements. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. Any forward-looking
statement reflects the Company's current views with respect to
future events and is subject to these and other risks, including
risks arising from uncertainties and assumptions relating to the
Company's operations, results of operations, growth strategy,
liquidity, HOPE Therapeutic's ability to consummate the
acquisitions of providers for its national network, the Company's
ability to raise adequate capital to fund such acquisitions, and
the Company's ability to spin-off HOPE Therapeutics. More
detailed information about the Company and the risk factors that
may affect the realization of forward-looking statements is set
forth in the Company's most recent Annual Report on Form 10-K and
other filings with the Securities and Exchange Commission.
Investors and security holders are urged to read these documents
free of charge on the SEC's website
at http://www.sec.gov. Except as may be required by
applicable law, The Company assumes no obligation to publicly
update or revise these forward-looking statements for any reason,
or to update the reasons actual results could differ materially
from those anticipated in these forward-looking statements, whether
as a result of new information, future events or otherwise.
For further information:
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-Chief Executive Officer, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaq-nrxp-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-17-2025-302399503.html
SOURCE NRx Pharmaceuticals, Inc.
